Saturday 22 May 2021

62nd Weekly Summit : The 6th Annual Academic International Medicine Congress 2021 (Virtual Edition) by ACAIM

 

www.ACAIM.org
AIM2021
Academic International Medicine Annual Congress
Best Practices in Shifting Landscapes

The Weekly Summit was held in partnership with the AIM2021 Congress. Members attended various sessions of the Congress.

Highlight Session:
Best Practices in International Research 
Research Education—Dr. Arun Kumar 
COVID Vaccine Research—Dr. Paul Kilgore 
Research Networks—Dr. Prashant Mahajan 
Strategic Analysis- Dr Joseph Hanna 
Research Capacity and Implementation- Dr Bhakti Hansoti

Key Note Address was delivered by NIH Fogarty International Center Chief Dr. Roger Glass. 

https://www.acaim.org/resources/Documents/AIM%202021%20Agenda%204.27.2021.pdf



61st WACEM-ACAIM Weekly Summit on Next Wave of COVID19

 15th May 2021

The 61st Weekly Summit Focused on bringing together experts on addressing the following issues

Preparedness for COVID19 for 3rd Wave

Mucormycotic Medication Formulary has to be specified and standardized for care.

Critical recognition of sick children is key for proper resource utilization.

Approval of Vaccine for 12 years and older lays additional burden on speeding the vaccine program.

Need for Planning is key

ACAIM2021 will held on 21-22-23 May 2021 and everyone for appraised and invited to attend.

www.ACAIM.org


Saturday 15 May 2021

60th WACEM-ACAIM Weekly Summit on Pediatric COVID19

8th May 2021

The 60th Weekly Summit Focused on bringing together experts on addressing the following issues

1.  Pediatric Immunization for COVID19

2. Pediatric Clinical Algorithms for COVID care

Inflammation is the major manifestation in Pediatric COVID patients.

Medication Formulary has to be specified and standardized for care.

Critical recognition of sick children is key for proper resource utilization.

Approval of Vaccine for 12 years and older lays additional burden on speeding the vaccine program.

Need for Planning is key

Following paper was Discussed:

2019 WACEM - Academic College of Emergency Experts Consensus Recommendations on Admission Criteria to Pediatric Intensive Care Unit from the Emergency Departments in India.

https://pubmed.ncbi.nlm.nih.gov/31198285/



Saturday 1 May 2021

59th Weekly Summit with ACAIM-WACEM Deciated to COVID19 Resurgence

 


Dr. Galwankar started this week's discussions by revisiting a concept proposed in early 2020 meetings by Dr. Irshad Choudry - that obesity is already a chronic inflammatory state. We visited the question of whether there is scope to control the state of inflammation, however given the prolonged, or rather sustained, state of inflammation, it unlikely for there to be a quick solution. Thiazolidinediones (glitazones) were proposed with a similar hypothesis in parts of the world, but held back because of their adverse effect profile. Lifestyle modifications are important, however, not a quick solution either. COVID-19 infections need us to act swiftly and often aggressively.

With that, we move to the combination of montelukast, colchicine, and aspirin - 'COVI-MAC'. Following from Dr. Sean Downing's theory, initially discussed in early 2020 as well, Dr. Vivek Chauhan shared his brilliant presentation. The pathophysiology of COVID-19 illness centers around hypoxia and multiorgan failure caused due to a cytokine release syndrome (and at its worst, a cytokine storm). It is proposed that montelukast and aspirin both inhibit the eicosanoid storm and NF-kappaB activation. Aspirin, of course, is also an antiplatelet agent. Colchicine is thought to be an inhibitor of inflammasomes. Individually, they have their own benefits, however, it is proposed that used in combination, the COVI-MAC regime would produce results, particularly when used as an early intervention in SARS-COV-2 positive patients. With due permissions and precautions, our teams are embarking on studies to move this beyond the hypothetical, to the practical and applicable.